Biogen's QALSODY Shows Promise in Slowing ALS Progression
TL;DR Summary
A new drug, tofersen, shows promise in slowing or reversing symptoms of a rare form of ALS by targeting the SOD1 mutation, with some patients experiencing significant improvements and reduced risk of death, marking a potential breakthrough in ALS treatment.
- New drug may slow progression of ALS in small group of patients: Study ABC News
- The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS Biogen
- Long-Term Tofersen Shows Benefit in SOD1-Mutated ALS Conexiant
- New ALS drug stabilizes decline with a trend toward improved strength, mobility for some WashU Medicine
- Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment GuruFocus
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
5 min
vs 5 min read
Condensed
96%
956 → 40 words
Want the full story? Read the original article
Read on ABC News